X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs AUROBINDO PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES AUROBINDO PHARMA PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
 
P/E (TTM) x 9.1 14.8 61.6% View Chart
P/BV x 3.0 3.8 79.0% View Chart
Dividend Yield % 0.8 0.4 197.4%  

Financials

 PIRAMAL ENTERPRISES   AUROBINDO PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
AUROBINDO PHARMA
Mar-17
PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,095895 234.1%   
Low Rs1,025622 164.8%   
Sales per share (Unadj.) Rs492.8254.6 193.6%  
Earnings per share (Unadj.) Rs72.639.3 184.7%  
Cash flow per share (Unadj.) Rs94.746.6 203.3%  
Dividends per share (Unadj.) Rs21.002.50 840.0%  
Dividend yield (eoy) %1.30.3 408.4%  
Book value per share (Unadj.) Rs862.5160.0 539.2%  
Shares outstanding (eoy) m172.56585.88 29.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.23.0 106.3%   
Avg P/E ratio x21.519.3 111.3%  
P/CF ratio (eoy) x16.516.3 101.2%  
Price / Book Value ratio x1.84.7 38.1%  
Dividend payout %28.96.4 454.7%   
Avg Mkt Cap Rs m269,194444,390 60.6%   
No. of employees `0004.014.0 28.7%   
Total wages/salary Rs m17,93917,678 101.5%   
Avg. sales/employee Rs Th21,190.310,667.8 198.6%   
Avg. wages/employee Rs Th4,470.11,264.3 353.6%   
Avg. net profit/employee Rs Th3,120.01,645.8 189.6%   
INCOME DATA
Net Sales Rs m85,037149,157 57.0%  
Other income Rs m2,3381,159 201.7%   
Total revenues Rs m87,374150,316 58.1%   
Gross profit Rs m34,99134,343 101.9%  
Depreciation Rs m3,8174,276 89.3%   
Interest Rs m20,310667 3,044.0%   
Profit before tax Rs m13,20230,558 43.2%   
Minority Interest Rs m1,69950 3,384.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2817,597 30.0%   
Profit after tax Rs m12,52023,012 54.4%  
Gross profit margin %41.123.0 178.7%  
Effective tax rate %17.324.9 69.5%   
Net profit margin %14.715.4 95.4%  
BALANCE SHEET DATA
Current assets Rs m87,59092,062 95.1%   
Current liabilities Rs m185,57866,223 280.2%   
Net working cap to sales %-115.217.3 -665.2%  
Current ratio x0.51.4 34.0%  
Inventory Days Days31106 29.3%  
Debtors Days Days4868 70.3%  
Net fixed assets Rs m108,52362,919 172.5%   
Share capital Rs m345586 58.9%   
"Free" reserves Rs m148,48193,133 159.4%   
Net worth Rs m148,82693,719 158.8%   
Long term debt Rs m144,9571,814 7,991.0%   
Total assets Rs m482,394162,494 296.9%  
Interest coverage x1.746.8 3.5%   
Debt to equity ratio x1.00 5,032.1%  
Sales to assets ratio x0.20.9 19.2%   
Return on assets %6.814.6 46.7%  
Return on equity %8.424.6 34.3%  
Return on capital %12.032.7 36.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00175,838 19.8%   
Fx outflow Rs m5,15030,224 17.0%   
Net fx Rs m9,85145,613 21.6%   
CASH FLOW
From Operations Rs m-100,39332,786 -306.2%  
From Investments Rs m-24,202-17,870 135.4%  
From Financial Activity Rs m135,705-19,153 -708.5%  
Net Cashflow Rs m11,110-4,239 -262.1%  

Share Holding

Indian Promoters % 52.9 54.1 97.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 8.0 50.3%  
FIIs % 26.6 27.7 96.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.2 161.8%  
Shareholders   93,274 69,601 134.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   IPCA LABS  GSK PHARMA  PANACEA BIOTECH  MERCK LTD  ABBOTT INDIA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 22, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS